Reading TYRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TYRA free→Reading TYRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TYRA free→QuarterlyIQ Insights · TYRA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 13, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 16, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors (the Board) of Tyra Biosciences, Inc. (the Company), and pursuant to the amended and restated bylaws of the Company, the Board approved an increase in the number of authorized directors from nine to ten and appointed Habib J. Da…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1, 2026, the Board of Directors of Tyra Biosciences, Inc. (the Company) designated Julia Rueb, Vice President, Finance of the Company, as the Company’s principal accounting officer, succeeding Alan Fuhrman, the Company’s Chief Financial Officer, in that role, each effective as of April 1, 2026. Mr. Fuhrman continues to be the Company’s pri…
Other Events. On March 4, 2026, Tyra Biosciences, Inc. (the “Company”) agreed to issue and sell 4,000,000 shares of common stock to a large investment management firm at a purchase price of $31.50 per share. The Company expects to receive $126.0 million in gross proceeds upon settlement, before deducting fees and other expenses payable by it. The shares of common stock are being issued as a block transaction under the Company’s “at-the-market” offering program, which has been registered under…
Results of Operations and Financial Condition. On March 2, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchan…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 25, 2025, the Board of Directors (the Board) of Tyra Biosciences, Inc. (the Company) appointed Bhavesh Ashar as the Company’s Chief Operating Officer, succeeding Daniel Bensen in that position, who was appointed the Company’s Chief Discovery Officer, each effective as of December 1, 2025. Mr. Ashar, 60, previously served as Chief Commer…
Results of Operations and Financial Condition. On November 5, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities…
Other Events. On August 21, 2025, Tyra Biosciences, Inc. (Tyra or the Company) announced the first child has been dosed in the BEACH301 Phase 2 clinical study of dabogratinib (formerly TYRA-300) in children with achondroplasia. The Company expects to report initial results from the safety sentinel cohort of the BEACH301 study in the second half of 2026. Forward-Looking Statements Tyra cautions you that statements contained in this report regarding matters that are not historical facts are for…
Results of Operations and Financial Condition. On August 14, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…
Other Events. On June 30, 2025, Tyra Biosciences, Inc. (Tyra or the Company) announced the first patient has been dosed in the SURF302 Phase 2 clinical study of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). SURF302 is an open-label Phase 2 clinical study evaluating the efficacy and safety of TYRA-300 in participants with FGFR3-altered low-grade, IR NMIBC. The study will enroll up to 90 participants at multiple sites primarily in the United States. Par…
Results of Operations and Financial Condition. On May 8, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…
Results of Operations and Financial Condition. On March 27, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 28, 2025, in connection with the appointment of a new director to the Board of Directors (the “Board”) of Tyra Biosciences, Inc. (the “Company”), Nina Kjellson resigned from the Board and the Compensation Committee of the Board effective as of January 29, 2025 (the “Effective Date”). Ms. Kjellson’s resignation from the Board and the Comp…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.